Send to

Choose Destination
Sex Transm Infect. 2011 Feb;87(1):41-3. doi: 10.1136/sti.2010.044412. Epub 2010 Oct 5.

Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11.

Author information

Département de Médecine Sociale et Préventive, Université Laval, Québec, Canada.



Given that the human papillomavirus (HPV) vaccine types have different durations of infectiousness and infectivity, the population-level vaccine effectiveness of these types may differ even if vaccine efficacy is identical.


To compare the type-specific effectiveness of vaccination against HPV types 16, 18, 6 and 11.


An individual-based stochastic model of HPV transmission (18 HPV-types) in a population stratified by age, gender and sexual activity was developed. Multiple parameter sets were identified by fitting the model to sexual behaviour data and age- and type-specific HPV prevalence.


Under base case assumptions (70% coverage, 99% vaccine efficacy per act and 20 years' duration of protection), vaccinating 12-year-old girls is predicted to reduce HPV-16, HPV-18 and HPV-6/11 prevalence by 61% (80% uncertainty interval (UI) 53-77), 92% (80% UI 65-100) and 100% (80% UI 97-100), respectively, 50 years after the start of the vaccination programme. Differences in type-specific vaccine effectiveness increased over time, and decreased with improved vaccine efficacy characteristics.


For the same vaccine efficacy, the population-level impact of HPV vaccination will most likely be different, with HPV-16, the most oncogenic type, having the lowest effectiveness. These results should be taken into account when designing and interpreting post-vaccination surveillance studies.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center